培美曲塞联合顺铂对晚期非小细胞肺癌的临床效果比较

被引：9

作者：

唐金凤 ^{[1
]}

余清平 ^{[2
]}

何倩 ^{[2
]}

机构：

[1] 长沙市中心医院药剂科

[2] 湖南中医药大学解剖教研室

来源：

肿瘤药学 | 2012年 / 2卷 / 01期

关键词：

多西紫杉醇; 培美曲塞; 顺铂; 晚期肺小细胞肺癌; 化疗;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100214 ;

摘要：

目的观察多西紫杉醇、培美曲塞单药或联合顺铂治疗晚期非小细胞肺癌(NSCLC)的近期疗效和毒性反应。方法选择85例入我院治疗的经病理学或细胞学确诊为晚期非小细胞肺癌的患者,随机分为四组并分别按以下方案进行化疗。PM组:培美曲塞500mg.m-2,第1天静脉滴注,21天为一周期;PC组:培美曲塞500mg.m-2第1天静脉滴注,顺铂75mg.m-2,第1～3天,21天为一周期;DC组:多西紫杉醇75mg.m-2,第1天、第8天,静脉滴注1h;DP组:多西紫杉醇75mg.m-2,第1天、第8天,静脉滴注1h,顺铂75mg.m-2分3天于第1～3天静脉滴注,21天为一周期。结果比较各组治疗有效率、疾病控制率、一年生存率无显著统计学差异(P>0.05)。比较DC组与DP组、PM组与PC组、DP组与PC组之间的无进展生存期差异有显著性(P<0.05);DC组与PM组比较两组差异无显著性(P>0.05)。DC组与DP组、PM组与PC组之间白细胞数减少发生率差异有统计学意义(P<0.05);各组间其他毒副反应的发生率差异无统计学意义(P>0.05)。结论多西紫杉醇、培美曲塞单药或联合化疗治疗进展或晚期NSCLC均有疗效,联合用药较单药化疗方案治疗晚期NSCLC的临床疗效更好,且不良反应轻。

引用

页码：44 / 47

页数：4

共 11 条

[1]

Overview of docetaxel/cisplatin combination in non-small cell lung cancer. Le Chavalier T,Berille J,Zaleberg JR,et al. Serain Oncol . 1999

[2]

Considerations for secondline therapy of non-small cell lung cancer. Stinchcombe TE,Socinski MA. The Oncologist . 2008

[3]

Treatment of advanced lung cancer in the elderly. Gajra A,Lichtman SM. Hosp Pract (Minneap) . 2011

[4]

Cancer statistics. Greenlee RT,Murray T,Bolden S,et al. CA Caneer J Clin . 2000

[5]

An overview of folate metabolism:features relevgnt to the action and toxicities of antifolate anticancer agents. Calvert H. Seminars in Oncology . 1999

[6]

Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer. Lee DS,Kim YS,Kang JH,et al. Cancer Res Treat . 2011

[7]

Elderly subgroup analysis of a randomized phaseⅢstudy of docetaxel plus platinum combinations versus vi-norelbine plus cisplatin for first-line treatment of advanced non small cell lung carcinoma(TAX326). Belani CP,Fossella F. Cancer . 2005

[8]

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Hanna N,Shepherd FA,Fossella FV,et al. Journal of Clinical Oncology . 2004

[9]

Chemotherapuetic management ofstageⅣNon-small cell lung cancer. Mark A,Socinsk I,David E,et al. Chest . 2003

[10]

Second-line therapy for NSCLC in clinical practice:baseline results of the European SELECTTION observational study. Moro-Sibilot D,Vergnenegre A,Smit EF,et al. Current Medical Research and Opinion . 2010

← 1 2 →